Comparative Effectiveness of Tocilizumab and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from the Rheumatic Diseases Portuguese Register, Reuma.pt
Table 2
Disease activity at 6-month follow-up and respective change from baseline.
Adalimumab ( = 106)
Etanercept ( = 202)
Golimumab ( = 43)
Infliximab ( = 78)
Tocilizumab ( = 95)
valu
TNFi ( = 429)
valu
DAS28 DAS28
3.8 ± 1.4 1.6 ± 1.4
3.5 ± 1.4 1.9 ± 1.4
3.5 ± 1.2 1.9 ± 1.4
3.8 ± 1.4 1.8 ± 1.4
2.8 ± 1.6 3.3 ± 1.6
<0.001 <0.001
3.6 ± 1.4 1.8 ± 1.4
<0.001 <0.001
CDAI ( = 327) CDAI
12.4 ± 9.3 15.1 ± 12.5
11.7 ± 10.0 16.1 ± 14.8
10.6 ± 6.5 16.0 ± 8.5
12.7 ± 10.2 17.0 ± 14.3
10.5 ± 10.3 22.7 ± 15.7
0.690 0.017
12.0 ± 9.6 16.0 ± 13.6
0.254 0.001
SDAI ( = 299) SDAI
13.7 ± 11.1 16.1 ± 13.3
12.4 ± 10.5 17.6 ± 16.1
13.1 ± 13.0 15.2 ± 11.6
14.0 ± 10.7 18.2 ± 14.9
11.6 ± 11.5 25.2 ± 16.5
0.778 0.007
13.1 ± 10.9 17.1 ± 14.7
0.343 0.0003
TJC28 TJC28
4.8 ± 5.8 6.3 ± 6.9
3.7 ± 5.4 6.5 ± 7.5
2.7 ± 3.2 6.5 ± 6.3
4.6 ± 5.9 6.6 ± 7.5
3.6 (4.8) 8.7 ± 7.7
0.109 0.100
4.0 ± 5.5 6.4 ± 7.2
0.508 0.006
SJC28 SJC28
2.3 ± 3.0 4.6 ± 4.8
1.7 ± 2.6 4.7 ± 4.9
2.3 ± 2.9 4.6 ± 4.4
2.2 ± 3.2 5.0 ± 4.9
2.6 ± 3.9 7.8 ± 6.6
0.179 <0.001
2.0 ± 2.9 4.7 ± 4.8
0.111 <0.001
ESR (mm/h, = 516) ESR
26.2 ± 21.6 10.1 ± 21.2
23.7 ± 19.4 13.5 ± 22.5
22.1 ± 15.1 15.5 ± 21.9
25.9 ± 21.0 12.0 ± 23.0
10.3 ± 14.5 35.2 ± 25.1
<0.001 <0.001
24.6 ± 19.9 12.6 ± 22.2
<0.001 <0.001
CRP (mg/dL, = 465) CRP
1.4 ± 2.7 0.7 ± 3.0
0.81 ± 1.4 1.2 ± 3.1
1.9 ± 7.3 0.1 ± 7.5
1.0 ± 1.7 1.0 ± 1.7
0.5 ± 1.3 2.3 ± 3.2
0.023 0.006
1.1 ± 2.9 0.9 ± 3.5
0.045 0.0009
PGH (mm, = 481) PGH
39.8 ± 25.8 18.7 ± 31.6
34.9 ± 23.8 21.5 ± 26.4
41.7 ± 22.0 18.3 ± 19.9
38.9 ± 24.9 21.5 ± 28.9
35.0 ± 24.0 25.5 ± 30.0
0.295 0.525
37.4 ± 24.4 20.5 ± 27.7
0.385 0.132
PhGA (mm, = 327) PhGA
25.8 ± 17.3 20.5 ± 21.4
24.0 ± 17.9 26.7 ± 23.2
22.7 ± 14.7 29.1 ± 19.1
28.3 ± 20.4 27.4 ± 21.6
20.0 ± 19.4 39.8 ± 25.6
0.160 0.0001
25.1 ± 18.0 25.5 ± 22.2
0.041 <0.001
HAQ ( = 323) HAQ
1.1 ± 0.7 0.5 ± 0.7
1.0 ± 0.7 0.4 ± 0.6
1.1 ± 0.7 0.3 ± 0.5
1.3 ± 0.7 0.3 ± 0.5
1.0 ± 0.7 0.6 ± 0.6
0.201 0.053
1.1 ± 0.7 0.4 ± 0.6
0.522 0.016
Absolute values and relative change in disease activity composite scores and markers at 6 months of therapy in rheumatoid arthritis patients, according to biologic therapy. Continuous variables presented as mean ± standard deviation; categorical variables are expressed as number (percentage). Final number of patients is indicated where there was missing data. value significant at <0.05; significant differences highlighted in bold. Comparison of groups according to biologic using ANOVA or chi-square test, as appropriate; comparison of TNFi versus tocilizumab groups using Student’s -test or chi-square test, as appropriate.
